Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate Cancer

N/ACompletedNCT00668083

AstraZeneca214 enrolled

Overview

Observational Retrospective trial on sequential hormonal therapy in patients with Prostate Cancer

Study Type

OBSERVATIONAL

Enrollment

214

Conditions

Prostate Cancer

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * non metastatic Prostate Cancer * previous treatment with bicalutamide 150mg * biochemical relapse/progression Exclusion Criteria: * use of other treatments for Prostate Cancer

Locations (12)

Research Site

Acquaviva delle Fonti, Italy

Research Site

Ancona, Italy

Research SIte

Florence, Italy

Research Site

Matera, Italy

Outcomes

Primary Outcomes

Hormonal sensitivity to second line treatment for CaP after Bicalutamide

Time frame: six months

Secondary Outcomes

median duration of second and third line treatments;

Time frame: six months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.